Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HINT1 | P49773 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717274 | 0.91 | KDM4E (0.41) | POLBKDM4EHINT1TAAR1STING1 | |
| SCHEMBL718291 | 0.89 | POLB (0.48) | POLBHINT1TAAR1STING1PDE3B | |
| SCHEMBL888190 | 0.84 | POLB (0.43) | POLBKDM4EHINT1STING1PDE3B | |
| SCHEMBL8003285 | 0.81 | POLB (0.51) | POLBHINT1TAAR1STING1PDE3B | |
| SCHEMBL15953158 | 0.76 | POLB (0.50) | POLBHINT1TAAR1STING1PDE3B | |
| SCHEMBL4578868 | 0.75 | POLB (0.46) | POLBHINT1STING1PDE3BPDE3A | |
| SCHEMBL16459760 | 0.74 | POLB (0.41) | POLBKDM4EHINT1STING1PDE3B | |
| SCHEMBL31098077 | 0.74 | POLB (0.47) | POLBKDM4EHINT1STING1PDE3B | |
| SCHEMBL31098008 | 0.74 | POLB (0.51) | POLBKDM4EHINT1STING1PDE3B | |
| SCHEMBL9548609 | 0.74 | POLB (0.52) | POLBKDM4EHINT1STING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-20210231609-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-11035823-B2 | Methods and devices for sequencing nucleic acids in smaller batches | QIAGEN SCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-10745740-B2 | Sample preparation | QIAGEN SCIENCES, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200149089-A9 | Sample Preparation | IsoPlexis Corporation | 2020-05-14 | — | — | US | disclosed |
| US-10472382-B2 | Methods and compositions for incorporating nucleotides | QIAGEN SCIENCES, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190285581-A1 | Methods and Devices for Sequencing Nucleic Acids in Smaller Batches | IsoPlexis Corporation | 2019-09-19 | — | — | US | disclosed |
| US-20130301888-A1 | Methods And Compositions For Base Calling Nucleic Acids | IsoPlexis Corporation | 2013-11-14 | — | — | US | disclosed |
| US-8481259-B2 | Methods and devices for sequencing nucleic acids in smaller batches | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137091-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20120052489-A1 | METHODS AND COMPOSITIONS FOR SEQUENCING NUCLEIC ACIDS USING CHARGE | INTELLIGENT BIO-SYSTEMS, INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110124054-A1 | Methods And Compositions For Inhibiting Undesired Cleaving Of Labels | INTELLIGENT BIO-SYSTEMS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20100330569-A1 | Hydroxymethyl Linkers For Labeling Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100323350-A1 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches | INTELLIGENT BIOSYSTEMS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100159531-A1 | Methods And Solutions For Inhibiting Undesired Cleaving Of Labels | INTELLIGENT BIO-SYSTEMS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100063743-A1 | Methods And Compositions For Base Calling Nucleic Acids | INTELLIGENT BIO-SYSTEMS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100035253-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885KDM4E 4166/4885HINT1 32/4885 |
| US-10472382-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | POLB 44/4885KDM4E 4166/4885HINT1 32/4885 |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885KDM4E 4166/4885HINT1 32/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885KDM4E 4166/4885HINT1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.